Cardiac toxicity induced by trastuzumab in a patient with breast cancer and literature review
CHEN Yang-yan
FAN Zai-wen
Abstract：One case of 45-year-old female patient diagnosed as left breast cancer with positive FISH detection of HER-2 underwent chemotherapy with paclitaxel and trastuzumab after 6 times of chemotherapy with pirarubicin. The initial therapy period of trastuzumab was 7 days (4 mg·kg-1) and changed to 21 days (6 mg·kg-1) after 2 chemotherapies. Six months later, the chemotherapy was changed to trastuzumab with the cycle for 21 days. Eighteen months later, the patient developed chest tightness and breathlessness with lower extremity edema, which was obvious after activities. Cardiac ultrasound showed the LVEF value was 33%. Cardiac dysfunction induced by trastuzumab was considered and the chemotherapy of trastuzumab was stopped. Deacetylase lanatoside, torasemide diuretic and levocarnitine were given for improving heart function, diuresis and nutrition myocardium for 10 days. Then the symptom disappeared, LVEF value recovered to 45%. After 4 months, LVEF value recovered to 51%.
Keywords：Breast cancerTrastuzumabCardiac toxicityAdverse drug reaction
Publication Date：2013-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 359-360,361 )